VERA
Vera Therapeutics, Inc. (VERA) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosures or ESG-specific updates were provided in the fresh data.
The company remains assessed primarily on financial resilience rather than reported environmental initiatives or liabilities.
Social
No new social, labor, or customer-related developments were reported in recent news.
There is insufficient fresh evidence to change the prior neutral assessment of social factors.
Governance
The company continues to show strong liquidity with a current ratio of 10.9 and cash ratio of 1.01, supporting governance-related financial stability.
Leverage remains modest with debt-to-equity of 0.18 and debt-to-assets of 0.14, but profitability and cash flow remain negative, which limits the overall governance quality assessment.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

